Ncardia Launches First Commercial iPSC-Derived Non-Human Primate Cardiomyocytes for Cardiac Safety Testing
核心洞察
Ncardia (搜索) has launched Ncyte® NHP-C vCardiomyocytes (搜索), the first commercially available ventricular-like cardiomyocytes (搜索) derived from cynomolgus monkey iPSCs for cardiac safety research.
The innovation provides a scalable, ethical alternative to live animal testing that closely mimics human cardiac electrophysiology and pharmacology for improved cardiotoxicity (搜索) prediction.
The new cell model enables cross-species mechanistic studies and supports pharmaceutical companies in meeting FDA's evolving expectations for reducing non-human primate use in safety testing.
Ncardia (搜索), a leader in stem cell-based solutions for drug discovery and safety assessment, announced the launch of Ncyte® NHP-C vCardiomyocytes (搜索), marking a significant breakthrough in cardiac safety research. These represent the first commercially available ventricular-like cardiomyocytes (搜索) derived from induced pluripotent stem cells (iPSCs) of cynomolgus monkeys, providing researchers with a scalable, ethical and translational tool for cross-species cardiac studies.
Addressing Critical Research Needs
The innovation addresses a growing need for physiologically relevant, non-human primate (NHP) in vitro models that reduce reliance on live animals in preclinical research. With this launch, Ncardia (搜索) empowers the scientific community to conduct cross-species mechanistic studies, improve predictive modeling of cardiotoxicity (搜索) and lower risk in drug development while advancing more ethical preclinical practices in alignment with FDA recent animal testing guidance.
Superior Functional Characteristics
Ncyte® NHP-C vCardiomyocytes (搜索) offer a high-purity, functional alternative that closely mimics human cardiac electrophysiology and pharmacology. The cells enable more predictive, scalable and ethical safety screening across species, supporting pharmaceutical and biotech companies in advancing safer therapies.
"As the only iPSC-derived NHP ventricular cardiomyocytes (搜索) on the market, Ncyte® NHP-C vCardiomyocytes (搜索) set a new standard for translational cardiovascular research," said Jeroen de Groot, divisional chief executive of Ncardia (搜索). "They give researchers the ability to perform direct cross-species comparisons in vitro, improve cardiotoxicity (搜索) risk assessment and meet the FDA's evolving expectations around reducing the use of live non-human primates in safety testing."
Impact on Drug Development
This breakthrough technology enables pharmaceutical and biotech companies to conduct more accurate cardiotoxicity (搜索) assessments while reducing their dependence on live animal models. The ability to perform direct cross-species comparisons in vitro represents a significant advancement in translational cardiovascular research, potentially accelerating the development of safer cardiac therapies.
The launch aligns with evolving regulatory expectations and ethical considerations in preclinical research, offering the scientific community a commercially viable alternative that maintains the physiological relevance necessary for robust safety assessment while supporting the principles of reducing animal testing in drug development.